MLL-PTD AML patients with FLT3-ITD had significantly higher WBC counts (63.5 vs. 14.9 × 109/L, P = 0.001), circulating blasts (71.8 vs. 61.7%, P = 0.036) and marrow blasts (82.9 vs. 69.3%, P = 0.001) than patients without FLT3-ITD. This evidence concerns the gene KMT2A and acute myeloid leukemia.